Biodesix, Inc.

Good day and thank you for standing by. Welcome to the Biodesic second quarter 2021 financial results and business update conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Chris Brinzey, Investor Relations. Please go ahead.

Thank you, Operator, and good afternoon, everyone. Thank you for joining us today for a discussion of Biodesics, second quarter 2021 business highlights and financial results. Leading the call will be Scott Hutton, Chief Executive Officer. Scott will then be joined by Robin Harper-Towie, Chief Financial Officer. After the prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call. Today we issued a press release announcing our business highlights and financial results for the second quarter 2021. A copy of the release can be found on the investor relations page of the company website. As a reminder, actual events or results may differ materially from those projected as a result of changing market trends, reduced demand, and the competitive nature of biodesics industry. Such forward-looking statements and their implications involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. The forward-looking statements discussed on this call are subject to other risks and uncertainties, including those discussed in the risk factors section and elsewhere in the company's annual report on Form 10-K, the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 16, 2021, as well as subsequent quarterly reports on Form 10-Q filed during 2021, if applicable. Additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in greater detail in the company's press release issued today and in the company's filings with the SEC. I would now like to turn the call over to Scott Hutton, Chief Executive Officer.

Scott? Thank you, Chris, and welcome, everyone, to Biodesic's second quarter 2021 earnings conference call. I'm planning to kick the call off with highlights. then turn it over to Robin for financials, then I'll come back with a deeper discussion on the business. Biodesics is a patient-centric, mission-driven diagnostics company. Our mission is to improve every patient's care by empowering physicians with swift, comprehensive, and actionable insights. To that end, it was a productive quarter with 180% year-over-year growth in total revenue. Our first four blood-based tests which make up our core lung diagnostic testing, grew 109% year over year and 20% over the prior quarter. We ended the quarter with $56.3 million in cash, which was a $1 million increase over Q1. In addition, we're happy to announce we're bringing forward the launch of our 72-hour liquid next-generation sequencing test to the beginning of next year. which will increase our core lung diagnostic testing menu to five tests. This broad portfolio of blood-based tests, coupled with our focused sales strategy, allows our sales team to provide multiple solutions for the same patient at various parts of their journey. The Biodesics portfolio of lung diagnostic tests is continuing to advance as well. We have multiple studies underway, including the Altitude, Beacon, Insight, and Oracle Prospective Studies to continue to build the data supporting our on-market test, as well as our pipeline test, including risk of recurrence and primary immune response. Our progress in the quarter reflects our commitment to improving patient outcomes through high-quality tests and clinical data. Now let me turn it over to Robin to review the second quarter financial performance. Robin?